INTRODUCTION
The number of Americans with more than 1 chronic condition is expected to rise from 60 million in 2000 to 81 million in 2020. 1 Although the increase in multimorbidity is being seen among middle-aged adults, growth is greatest in those 65 years old or older. 2 According to self-report data from the 2009-2010 National Health Interview Survey, 45% of adults who were 65 years old or older reported at least 2 of 9 chronic conditions (hypertension, heart disease, diabetes, cancer, stroke, chronic bronchitis, emphysema, current asthma, and kidney disease); this represented a 37% increase in comparison with the 1999-2000 survey. 2 Multimorbidity is associated with decrements in quality of life and functional status and increased health care utilization. [3] [4] [5] [6] Cancer affects 40.8% of adults during their lifetime. 7 The incidence of cancer in those older than 65 years is 10 times greater than the incidence in those younger than 65 years. 8 With increasing age, those diagnosed with cancer are much more likely to have 1 or more preexisting chronic conditions. Cancer patients with comorbidities have poorer survival and often do not receive various standard cancer and supportive-care therapies. [9] [10] [11] The impact of cancer and preexisting comorbidities on patients' symptom burden is only beginning to be appreciated. Although a few studies have highlighted the impact of multimorbidity on the receipt of cancer treatment, 12 fatigue and pain symptoms, 13 and mortality, 14 data on how comorbidity influences a patient's illness experience and overall symptom burden are sparse. To address this gap, we conducted a secondary analysis with data from the E2Z02 Symptom Outcomes and Practice Patterns (SOAPP) study, which is a large-scale, multicenter, prospective, observational study describing the prevalence and severity of common symptoms in oncology outpatients over a 1-month period. The aims of the current analysis were to examine the associations between 1) the number of comorbidities, 2) the patient-reported symptom burden, 3) the patient-reported bother from comorbid conditions, and 4) the patient-reported bother from cancer. We also examined the association between these variables and clinician-reported difficulty in caring for patients' symptoms.
MATERIALS AND METHODS

Patients
All patients included in this report were enrolled in the SOAPP study. A full description of the methods has been published elsewhere. 15 In total, 3123 oncology outpatients at any point in the trajectory of their care for invasive breast, lung, prostate, or colorectal cancer were enrolled in the SOAPP study between March 2006 and May 2008. Eligible patients had to be at least 18 years old, receiving care at an Eastern Cooperative Oncology Group-affiliated institution, willing to complete the follow-up survey, and judged by the study screener to have cognitive function adequate for completing study surveys. Patients were registered at 38 institutions, including 6 academic sites and 32 community clinics. Patients treated at academic centers were enrolled from disease site-specific clinics. In contrast, patients treated at community clinics were enrolled from general oncology clinics. Patients were recruited when they checked in for their clinic appointments, and patient information was collected before their visit with a clinician. Patients and their treating oncology clinicians were surveyed at the initial visit and at followup 28 to 35 days later. Further details about the study cohort have been published. 16 The protocol was approved by the institutional review boards at each registering institution. All patients provided written informed consent.
Measures
Patients' clinical and demographic information, including cancer treatment history and current therapies, were collected at the baseline via patient-specific and providerspecific surveys. The protocol and case report forms are accessible at the study's Web site (http://www.ecogsoapp. com/).
Symptom burden
Patients completed the modified 19-item MD Anderson Symptom Inventory (MDASI), a validated patient symptom assessment. [17] [18] [19] Thirteen items measure physical symptoms: pain, nausea, shortness of breath, lack of appetite, dry mouth, vomiting, numbness/tingling, diarrhea, constipation, sore mouth, skin rash, hair loss, and coughing. Patients rated each symptom "at its worst" in the previous 24 hours, regardless of its causes, with an 11-point numeric scale ranging from 0 ("not present") to 10 ("as bad as you can imagine"). We defined the symptom burden as the number of severe symptoms rated as 7 on the MDASI's 0 to 10 scale on the basis of results from various studies. 18, 20 Number of comorbidities
The presence of comorbid conditions was not collected in the original study. However, the use of chronic medications was collected. We, therefore, used medication data to identify chronic comorbid conditions with RxRisk. RxRisk is an adaptation of the Chronic Disease Score that uses pharmacy dispensing data to identify classes of medications that are taken as proxies for the existence of chronic disease. The Chronic Disease Score has shown anticipated relations with functional status, health service use, and mortality. [21] [22] [23] In the SOAPP study, clinicians reported patients' specific medications at the baseline via the medication form, including those that were newly prescribed. In the current report, using RxRisk, we identified the presence of chronic comorbid conditions requiring ongoing management by the report of specific medications linked to those conditions. A patient was considered to have a specific disease if the patient was initiating/continuing the medications commonly used for the treatment of the disease at study entry (Supporting Table 1 In the study, general patient perceptions about cancer and comorbidity were assessed with exploratory items asking patients about their level of "bother" from these areas. General health perception is part of the health-related
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Cancer quality of life model described by Wilson and Cleary, 24 which links biological and physiological factors, symptoms, functioning, and general health perceptions to overall quality of life. Patients rated how bothered they were by "difficulties related to health problems other than cancer" with a 5-point scale ranging from "not at all" to "extremely." Patients rated their bother due to cancer in a similar way.
Clinician-reported difficulty in managing patients' symptoms
For each enrolled patient, his or her oncology clinician was asked the following: "Relative to other patients with same stage of disease, how would you categorize the degree of difficulty in caring for this patient's physical/psychological symptoms?" Potential responses included "very difficult," "difficult," "average," "easier than average," and "much easier than average."
Statistical Analysis
The association between categorical and binary variables was examined with the chi-square test. Linear regression models were constructed to examine how the number of comorbid conditions affected the symptom burden. Logistic regression models were used to examine the associations between the numbers of comorbidities, the symptom burden, and the bother due to cancer and due to comorbidities and to explore factors associated with clinician-reported difficulty in caring for patients' symptoms. The adjusted covariates were the same in all models and included the following: age, years since diagnosis, race/ethnicity, disease status, disease stage, Eastern Cooperative Oncology Group performance status, weight loss in the past 6 months, prior systemic therapy, prior radiotherapy, current therapy, total number of current medicines, individual counseling, and participation in a support group. The variance inflation factor was used to check multicollinearity among covariates in the multivariate regression models (variance inflation factor < 3 for all variables). Major model assumptions (independence, equal variance, normality, and linearity) were checked for linear models, and Hosmer-Lemeshow tests were used to check the model fit for logistic models. A few variables had some modest missing data, and a separate category for missing data was generated for categorical covariates if the proportion of missingness was greater than 5%. Otherwise, patients with missing data were excluded from the regression models. Clustered sandwich estimators of standard errors were used in all regression models to account for the clustering effect of institutions. All P values were 2-sided, and P < .05 was considered statistically significant. No adjustment was made for multiple comparisons. Stata 13.1 software (2009; StataCorp, College Station, Texas) was used for all data analysis. Table 1 summarizes the sample's clinical and demographic characteristics as well as the prevalence and types of comorbidities. Of the 3123 total patients, 3106 patients were analyzed. Of those, 50% had breast cancer, 23% had colorectal cancer, 17% had lung cancer, and 10% had prostate cancer. The median age was 61 years. Overall, 2432 patients (78%) reported initiating or continuing medications for at least 1 of the 12 comorbid conditions; 18% had 1 comorbid condition, and 19% had 5 or more comorbid conditions. The most common comorbid condition was hypertension (45%), which was followed by anxiety/tension/psychotic illness (35%). In multivariate linear regression models, lung cancer, increased age, minority status, increased time since cancer diagnosis, poor performance status, taking more medications, and receiving counseling were associated with more comorbid conditions (data not shown). Patients who had metastatic cancer, were currently receiving cancer treatment, or were participating in a support group were likely to report fewer comorbid conditions (data not shown).
RESULTS
Patient Characteristics and Comorbidity Prevalence
Symptom Burden and Its Association With Comorbidity
Approximately 39% of the patients reported having at least 1 severe symptom (ie, they rated the severity of at least 1 symptom as 7; Table 2 ). The proportion increased with an increasing number of comorbid conditions (48% vs 36% for patients with 5 vs 1 comorbid conditions). With the exception of skin rash and hair loss, the percentage of severe symptoms (7) was highest among those with the highest number of comorbid conditions (Supporting Table 2 [see online supporting information]). The multivariate linear regression analysis showed a positive linear association between the number of comorbid conditions and the patient-reported symptom burden (P < .001) after adjustments for cancerrelated factors and other variables (model 1 in Table 3 ). Cancer-related factors (no response to cancer therapy, prior systemic therapy, and current cancer treatment) were significantly associated with an increased symptom burden as well (data not shown). Other characteristics associated with an increased symptom burden included a younger age, minority status, poor performance status, and >5% weight loss in the past 6 months (data not shown).
Patient-Reported Bother From Comorbidity and From Cancer
One-third of the patients were bothered moderately or worse by comorbidity, and the proportion increased with an increasing number of comorbid conditions (23.8%, 31.1%, 36.6%, 36.2%, and 49.0% for 1, 2, 3, 4, and 5 comorbid conditions, respectively; P trend < .001; Table  2 ). There was also a strong positive association between the patient-reported symptom burden and patientreported bother due to comorbidity. Among those not or slightly bothered by comorbidity, 1 or more symptoms were rated as 7 or worse by 33% of the patients versus 52% of the patients at least moderately bothered by comorbidity (Fisher's exact P < .001). In addition, the proportion of patients' ratings 7 for each symptom (except for hair loss) was higher among patients reporting moderate or worse bother from comorbidity (data not shown). These associations remained significant in the multiple logistic regression analysis adjusted for other covariates (model 2 in Table 3 ). Patients had 2.4 times higher odds (95% confidence interval [CI], 1.8-3.2) of being moderately or more severely bothered by comorbidity if they had 5 or more comorbid conditions versus no comorbidity. The odds of being bothered by comorbidity increased by 22% with every additional symptom rated as severe (ie, 7). Patients who had breast cancer, a longer Original Article period since their cancer diagnosis, or a poor performance status or were receiving counseling services were more likely to be bothered by comorbidity (data not shown). Approximately half of the patients reported moderate or worse bother from cancer, and it was significantly associated with cancer characteristics (lung cancer, a shorter period since the cancer diagnosis, advanced disease, and no response to cancer treatment) and symptom burden. This did not change with an increasing number of comorbid conditions (model 3 in Table 3 ).
Clinician-Reported Difficulty in Managing Patients' Symptoms
In comparison with patients with the same stage of disease, clinicians reported greater difficulty in caring for patients' physical/psychological symptoms if the patients reported a greater symptom burden (odds ratio [OR], 1.1; 95% CI, 1.1-1.2), greater bother from comorbidity (OR, 1.6; 95% CI, 1.2-2.1), or greater bother from cancer (OR, 2.0; 95% CI, 1.4-2.8; model 4 in Table 3 ). It was not associated with the number of comorbidities. Breast cancer, a non-complete response status, no current cancer treatment, an older age, and a poor performance status were associated with the provider's perception of increased difficulty in providing care (data not shown).
DISCUSSION
To our knowledge, the SOAPP study is the largest prospective evaluation of comorbidity and symptom burden in outpatient oncology patients with solid tumors in the United States to date. This secondary analysis of the SOAPP study shows that the presence of multiple chronic comorbid conditions is quite common in cancer patients and that the number of comorbid conditions is positively associated with the patient-reported symptom burden, with adjustments for cancer-related factors. Few other studies have examined this relation. In Hung et al's relatively small study of 134 colorectal cancer patients, 19 the presence of comorbidity was associated with increased pain but not with increased overall physical symptoms. In a systemic review limited to breast cancer, the number of comorbid conditions increased with age and was associated with symptom burden, functional decline, and low adherence to surveillance as well as decreased quality of life; however, this study did not describe patient-reported bother and symptom severity. 25, 26 In a systematic review of cancer-related fatigue, comorbidity was associated with increased levels of fatigue; however, no other symptoms were evaluated, nor was patient-reported bother. 27 In the Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) study, lung or colorectal cancer patients with limited financial reserves were more likely to have a higher symptom burden and decreased quality of life; however, financial reserve was the main focus of the study, and comorbidity or bother due to other symptoms was not examined. 28 None of the previous studies looked for clinician-reported difficulty in patient management and how it related to patients' experience of comorbidity or symptom burden. It is not uncommon to attribute patients' symptoms to cancer, 29 but the results of this analysis suggest that comorbidity should be adequately acknowledged and thoroughly considered as a contributor to symptom burden for the management of cancer patients.
Our study also suggests that patients with advanced cancer, those receiving active cancer treatment, and support-group participants had fewer comorbid conditions. This finding is consistent with previous studies, which have reported that compared with patients without comorbidity, those with more comorbidities may be less likely to receive standard cancer treatment. 9, 12 Thus, decisions related to cancer treatment may depend not only on the type and stage of cancer but also on the type and severity of the comorbidity rather than the number of comorbidities. It should be noted, however, that the relation between comorbidity and metastatic cancer may be confounded by the methodology by which the comorbidity is ascertained. Our study identified comorbidities through the patients' exposure to active medications for a chronic condition. It is possible that for a subset of patients with advanced cancer, medications for some chronic conditions were discontinued or did not appear on their medication list, and this decreased our ability to capture these comorbid conditions.
Overall, we found that approximately one-third of cancer patients are at least moderately bothered by comorbidity. Mental health comorbidity was common. The number of comorbid conditions, symptom burden, duration of cancer, age, and performance status were all associated with bother from comorbidities. Bother from comorbidities may be an indicator of the treatment burden, a concept only recently being appreciated in the multimorbidity literature. 30 Patient-reported bother from comorbid health problems and from cancer was positively associated with clinician-reported difficulty in caring for a patient's physical/psychological symptoms in comparison with patients with the same stage of disease. Because the treatment burden is influenced by the particular treatment that a condition requires (eg, diabetes requires more interventions than hypertension), it is not altogether surprising that the degree to which patients were bothered by their comorbid conditions was of greater importance than the number of comorbidities. Bother due to both cancer and comorbid conditions plays an important role in the patient experience and also appears to serve as an indicator for complexity in patient care. The careful exploration of the determinants of bother and symptom burden, focusing not only on the patient's underlying cancer but also on his or her comorbid conditions, may improve the overall quality of life. With aging and the increasing prevalence of chronic cooccurring conditions, clinical challenges associated with comorbidity will increase. Because comorbidity is associated with symptom burden and perceived care complexity, clinicians and health systems will have to attend to the interplay between comorbid conditions, solid tumor treatment, and symptom management.
There are several important limitations to the study. First, the analyses presented in this article represent a secondary data analysis from the large, prospective, multicenter SOAPP study. Second, although it is not an uncommon practice for comorbidity assessment, the measurement of comorbidity was derived from medication data. In this cancer population, 12 comorbid conditions were definitively identified from medication data. Although this list may not have included every condition, it provided a list of actively treated conditions most likely to contribute to disease burden. Third, the symptom burden was measured with the MDASI physical scale and considered only the severity of the symptom in the previous 24 hours; it did not capture chronicity. Fourth, the term bother, though common and understandable in everyday life, may represent more than 1 domain, including general health perception and illness or treatmentrelated burden. This exploratory item from the SOAPP study is worthy of further study. That the number of comorbidities was not associated with patient-reported bother from cancer (but was associated with patientreported bother from comorbidities) supports the idea that patients were effective in distinguishing between the cancer and comorbid conditions. Lastly, these findings can be generalized only to patients with common solid tumors who receive care at academic and community sites associated with the US National Cancer Institute's Clinical Trials Network.
In conclusion, comorbidity is common in cancer patients, and the symptom burden varies significantly according to the number of comorbid conditions. Clinicians may enhance the care of patients with cancer by taking into account the role of comorbidities in their symptom burden. Future research should focus prospectively and longitudinally on the role of multiple cooccurring conditions in symptom burden, treatment complexity, patient experience, and overall illness burden with the goal of reducing the suffering and improving the quality of life for patients with solid tumors.
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